Literature DB >> 22212231

Erythropoietin and myocardial infarction.

Fabian Sanchis-Gomar, Vladimir E Martinez-Bello, Giuseppe Lippi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22212231      PMCID： PMC5439821          DOI： 10.1111/j.1752-8062.2011.00360.x

Source DB:  PubMed          Journal:  Clin Transl Sci        ISSN： 1752-8054            Impact factor:   4.689


× No keyword cloud information.
  5 in total

1.  Evaluation of agents to reduce infarct size: it can be quite REVEALing.

Authors:  Deepak L Bhatt
Journal:  JAMA       Date:  2011-05-11       Impact factor: 56.272

Review 2.  Arterial thrombus formation in cardiovascular disease.

Authors:  Giuseppe Lippi; Massimo Franchini; Giovanni Targher
Journal:  Nat Rev Cardiol       Date:  2011-07-05       Impact factor: 32.419

3.  Effects of combination of proliferative agents and erythropoietin on left ventricular remodeling post-myocardial infarction.

Authors:  Rosemeire M Kanashiro-Takeuchi; Lauro M Takeuchi; Konstantinos Hatzistergos; Henry Quevedo; Sarah M Selem; Adriana V Treuer; Courtney Premer; Wayne Balkan; Irene Margitich; Yun Song; Qinghua Hu; Joshua M Hare
Journal:  Clin Transl Sci       Date:  2011-06       Impact factor: 4.689

4.  Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: REVEAL: a randomized controlled trial.

Authors:  Samer S Najjar; Sunil V Rao; Chiara Melloni; Subha V Raman; Thomas J Povsic; Laura Melton; Gregory W Barsness; Kristi Prather; John F Heitner; Rakhi Kilaru; Luis Gruberg; Vic Hasselblad; Adam B Greenbaum; Manesh Patel; Raymond J Kim; Mark Talan; Luigi Ferrucci; Dan L Longo; Edward G Lakatta; Robert A Harrington
Journal:  JAMA       Date:  2011-05-11       Impact factor: 56.272

5.  Hematocrit level as a marker of outcome in ST-segment elevation myocardial infarction.

Authors:  Gabriel Greenberg; Abid Assali; Hanna Vaknin-Assa; David Brosh; Igal Teplitsky; Shmuel Fuchs; Alexander Battler; Ran Kornowski; Eli I Lev
Journal:  Am J Cardiol       Date:  2010-01-05       Impact factor: 2.778
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.